Literature DB >> 17681703

Inhibition of TLR4 signaling pathway: molecular treatment strategy of periodontitis-associated atherosclerosis.

Bin Huang1, Huangqin Chen, Mingwen Fan.   

Abstract

The accumulation of epidemiologic, pathologic, and animal model studies suggests that periodontal infection may be a contributing risk factor for atherosclerosis. The Toll-like receptor-4 (TLR4) signaling pathway plays an important role in the initiation and progression of periodontitis-associated atherosclerotic disease. We postulate that suppression of TLR4 signaling pathway can be an effective treatment for atherosclerosis. These strategies include prevention of ligand binding to TLR4, blocking the interactions of TLR4s and adaptors in signaling pathways, blocking the enzymes in signaling pathways, and immunostimulation with vaccine adjuvants. However, we should be aware that there may be unknown risks about the new technologies and these drugs, which may cause some unknown side effects in long-term administration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17681703     DOI: 10.1016/j.mehy.2007.06.015

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  3 in total

1.  Molecular pathways mediating differential responses to lipopolysaccharide between human and baboon arterial endothelial cells.

Authors:  Qiang Shi; Laura A Cox; Jeremy Glenn; Maria E Tejero; Vida Hondara; John L Vandeberg; Xing Li Wang
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-07-24       Impact factor: 2.557

2.  Ufm1 inhibits LPS-induced endothelial cell inflammatory responses through the NF-κB signaling pathway.

Authors:  Yuan-Yuan Li; Guang-Ya Zhang; Jiang-Ping He; Dan-Dan Zhang; Xiang-Xin Kong; Hui-Min Yuan; Feng-Ling Chen
Journal:  Int J Mol Med       Date:  2017-04-07       Impact factor: 4.101

3.  Resveratrol Inhibits MMP3 and MMP9 Expression and Secretion by Suppressing TLR4/NF-κB/STAT3 Activation in Ox-LDL-Treated HUVECs.

Authors:  Ming Zhang; Yun Xue; Huilian Chen; Lingbing Meng; Beidong Chen; Huan Gong; Yanyang Zhao; Ruomei Qi
Journal:  Oxid Med Cell Longev       Date:  2019-09-10       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.